The Ensign Group Inc - Company Profile
Powered by
All the data and insights you need on The Ensign Group Inc in one report.
- Save hours of research time and resources with
our up-to-date The Ensign Group Inc Strategy Report
- Understand The Ensign Group Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
The Ensign Group Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of The Ensign Group Insights data
Headline | Published | Journalists |
---|---|---|
Deserunt mollit sunt Lorem laborum do id aliqua dolore | 29 Feb 2016 | Lorem |
Cornerstone Pharma plans multiple CPI-613 Phase II trials by YE16 | 29 Feb 2016 | Manasi Vaidya |
Phase I T-cell lymphoma study of cancer-metabolism drug CPI-613 nearly halfway enrolled, B-cell NHL study lags – investigator | 16 Sep 2015 | Alaric DeArment |
Cornerstone’s lixivaptan has good chance for Phase III BALANCE success and approval in hyponatremia, experts say | 14 Aug 2012 | Anusha Kambhampaty |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer